Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
Teva藥品在歐洲神經學會大會上展示了PEARL偏頭痛預防研究的第4次中期分析；新的亞分析突出了治療暫停對患者結果的潛在負面影響
- 4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki
- New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes1
- Sub-analysis exploring impact of treatment cessation and reinitiation on migraine prevention suggests potential rise in migraine attacks and diminished treatment effectiveness upon reinitiation1
- PEARL實際世界偏頭痛預防研究的第4次中期分析在赫爾辛基舉行的第10屆歐洲神經學協會（EAN）大會上展示。
- PEARL數據的新子分析突出了治療暫停對患者結果的潛在負面影響1。
- 探討治療停止和重新開始對偏頭痛預防的影響的子分析表明，在重新開始後可能會出現偏頭痛發作和治療效果降低1。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。